FBTAX
Fidelity Adv Biotechnology-A
Biotechnology: A Niche with High Growth Potential
Fidelity Adv Biotechnology-A (FBTAX) stands out as a specialized mutual fund with a laser focus on the biotechnology sector. This fund is designed for investors seeking capital appreciation by investing at least 80% of its assets in equity securities of firms engaged in the research, development, distribution, and manufacture of various biotech products, services, and processes. The fund’s strategic focus on biotechnology allows it to capitalize on the rapid advancements and innovations within this dynamic industry. Managed by Fidelity Investments, a well-respected name in the financial world, FBTAX offers investors a unique opportunity to gain exposure to both domestic and international biotech firms. This focus on a single sector, while potentially increasing risk, also provides the potential for significant returns, as evidenced by its impressive 1-year return of 54.33%.
At A Glance
Executive Summary
FBTAX focuses on biotech equities, offering high growth potential with a 54.33% 1-year return. It has a 0.96% expense ratio and invests heavily in U.S. equities.
– High 1-year return of 54.33%. – Strong focus on biotechnology sector. – Managed by Fidelity Investments, a reputable firm. – High alpha of 21.08%, indicating strong performance over the benchmark.
– High beta of 1.28, indicating higher volatility. – Sector-specific focus may lack diversification. – Expense ratio of 0.96% is higher than some peers.
Performance: Riding the Wave of Biotech Innovation
FBTAX has demonstrated remarkable performance, particularly over the past year, with a 1-year return of 54.33%, significantly outperforming its benchmark, the MSCI World DivAdj Index, which returned 33.21% over the same period. This outperformance can be attributed to the fund’s strategic allocation to high-performing biotech stocks such as AbbVie Inc and Amgen Inc, which are among its top holdings. Over a 10-year period, the fund has maintained a steady return of 8.56%, showcasing its ability to deliver consistent growth over the long term. The fund’s performance is further highlighted by its high alpha of 21.08%, indicating that it has generated returns well above the expected benchmark performance. This success is a testament to the fund’s effective management and its ability to navigate the complexities of the biotech sector.
Risk Profile: Balancing High Returns with Volatility
FBTAX presents a risk profile characterized by a beta of 1.28, indicating that it is more volatile than the broader market. This higher volatility is a reflection of its concentrated focus on the biotechnology sector, which is inherently more volatile due to its reliance on innovation and regulatory approvals. The fund’s Sharpe ratio of 1.09 suggests that it has been able to achieve a favorable risk-adjusted return, balancing the potential for high returns with the associated risks. The fund’s downside risk, as measured by its downside risk (UI) of 4.53, and its max drawdown of -11.7%, highlight the potential for significant fluctuations in value. However, the fund’s ability to recover from drawdowns, with a recovery length of just three months, demonstrates its resilience and the potential for investors to benefit from its high upside potential of 4.65.
Portfolio Composition: A Deep Dive into Biotech Holdings
The portfolio of FBTAX is heavily weighted towards the healthcare sector, with 100% of its sector allocation dedicated to this area. This concentration is further reflected in its top holdings, which include major biotech players such as AbbVie Inc, Amgen Inc, and Regeneron Pharmaceuticals Inc. These companies are at the forefront of biotech innovation, driving the fund’s performance. The fund’s allocation strategy is also evident in its market cap distribution, with a significant portion invested in large-cap stocks, which tend to offer stability and growth potential. The fund’s focus on U.S. equities, which make up 88.48% of its asset class allocation, underscores its commitment to investing in the leading biotech firms in the world. This strategic allocation not only positions the fund to benefit from the growth of the biotech sector but also aligns with its objective of capital appreciation.
Income Strategy: Yielding Opportunities in Biotech
FBTAX offers a yield of 0.91%, which, while modest, is consistent with its focus on capital appreciation rather than income generation. This yield is competitive within the biotech sector, where many companies reinvest profits into research and development rather than paying dividends. For income-focused investors, this fund may not be the primary choice, but for those seeking growth, the yield provides a small additional return. The fund’s income strategy is aligned with its objective of investing in firms that are poised to benefit from advances in biotechnology, offering potential for capital gains as these companies grow and innovate. This makes FBTAX an attractive option for growth-focused investors who are willing to accept a lower yield in exchange for the potential of higher long-term returns.
Cost Considerations: Evaluating the Expense Ratio
The expense ratio of FBTAX stands at 0.96%, which is relatively high compared to some of its peers in the mutual fund space. This higher expense ratio reflects the specialized nature of the fund and the expertise required to manage a portfolio concentrated in the biotechnology sector. While this cost may impact net returns, it is important to consider the fund’s strong performance and the potential for high returns, which can offset the higher expenses. When compared to similar funds, FBTAX’s expense ratio is competitive, especially given its focus on a high-growth sector. Investors should weigh the cost against the potential benefits of investing in a fund that offers exposure to cutting-edge biotech firms and the expertise of Fidelity Investments.
Peer Comparison: Standing Out in a Competitive Landscape
When compared to similar funds, FBTAX distinguishes itself through its focused investment strategy and strong performance metrics. While funds like Janus Henderson Global Tech & Innovation-A (JATAX) and DWS Science & Technology-A (KTCAX) offer competitive returns, FBTAX’s 1-year return of 54.33% is among the highest in its category. Additionally, its high alpha of 21.08% indicates superior performance relative to its benchmark. However, its expense ratio of 0.96% is higher than some peers, which may be a consideration for cost-conscious investors. Despite this, FBTAX’s unique focus on biotechnology and its ability to deliver strong returns make it a compelling choice for investors seeking exposure to this dynamic sector.
Future Outlook
The fund’s focus on biotechnology positions it well for growth, especially with ongoing advancements in the sector. It may benefit from increased healthcare spending and innovation. However, its performance is sensitive to market volatility and sector-specific risks.
Investor Suitability: Tailoring to Growth-Oriented Investors
FBTAX is ideally suited for investors with a high risk tolerance and a focus on long-term growth. Its concentrated investment in the biotechnology sector offers the potential for significant capital appreciation, making it an attractive option for growth-focused investors. The fund’s high beta and sector-specific focus may not be suitable for conservative investors or those seeking diversification across multiple sectors. However, for those willing to embrace the volatility associated with biotech investments, FBTAX provides an opportunity to capitalize on the advancements and innovations within this rapidly evolving industry. Investors who are comfortable with the risks and are seeking exposure to cutting-edge biotech firms will find FBTAX to be a valuable addition to their portfolio.
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
W3sicmV0dXJucyI6IjI3LjE4JSIsInllYXIiOiIyMDI0In0seyJyZXR1cm5zIjoiMTAuNjglIiwieWVhciI6IjIwMjMifSx7InJldHVybnMiOiItNy45NSUiLCJ5ZWFyIjoiMjAyMiJ9LHsicmV0dXJucyI6Ii0zLjU2JSIsInllYXIiOiIyMDIxIn0seyJyZXR1cm5zIjoiMzIuMTYlIiwieWVhciI6IjIwMjAifSx7InJldHVybnMiOiIyNS43MCUiLCJ5ZWFyIjoiMjAxOSJ9LHsicmV0dXJucyI6Ii0zLjc4JSIsInllYXIiOiIyMDE4In0seyJyZXR1cm5zIjoiMjUuODElIiwieWVhciI6IjIwMTcifSx7InJldHVybnMiOiItMjMuNTklIiwieWVhciI6IjIwMTYifSx7InJldHVybnMiOiIxMS4wOCUiLCJ5ZWFyIjoiMjAxNSJ9XQ==
Similar Securities
Fidelity Adv Health Care-I – FHCIX
Fidelity Adv Biotechnology-A – FBTAX
Fidelity Select Health Care Service – FSHCX
Vanguard Health Care-Inv – VGHCX
Fidelity Select Biotechnology – FBIOX
Fidelity Select Health Care – FSPHX
Fidelity Select Pharmaceuticals – FPHAX
Fidelity Select Medical Tech & Devices – FSMEX
Disclaimer: The information provided on this website is for informational purposes only and should not be construed as financial, investment, or other professional advice. PeepFinance does not endorse or recommend any specific securities, investments, or strategies. The opinions expressed are solely those of the authors and are not intended to be used as the basis for any investment decisions. All investments carry risks, and readers are encouraged to conduct their own research or consult with a financial professional before making any financial decisions. PeepFinance and its authors are not responsible for any losses or damages arising from the use of this information.